ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.768,82
0,92%
S&P 500
6.061,75
0,59%
US Dollar vs BRL
5,786
-0,35%
Bitcoin
96.990,00
0,51%
Brent Oil
75,795
1,57%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) Notícias

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EPRX
DataHoraFonteTítuloCódigoCompanhia
20/11/202410:57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
20/11/202409:00PR Newswire (US)Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/11/202419:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNASDAQ:EPRXEupraxia Pharmaceuticals Inc
13/11/202419:00PR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
12/11/202419:56PR Newswire (US)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/11/202413:49Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202419:00PR Newswire (US)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202418:10Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:EPRXEupraxia Pharmaceuticals Inc
31/10/202420:36PR Newswire (US)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionNASDAQ:EPRXEupraxia Pharmaceuticals Inc
28/10/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
15/10/202408:00PR Newswire (Canada)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/10/202418:01PR Newswire (Canada)Eupraxia Pharmaceuticals Strengthens Senior Management TeamNASDAQ:EPRXEupraxia Pharmaceuticals Inc
19/09/202418:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/09/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/09/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/08/202408:00PR Newswire (US)Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt FacilityNASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/07/202408:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and ExpoNASDAQ:EPRXEupraxia Pharmaceuticals Inc
03/07/202418:00PR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/06/202418:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/06/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
23/05/202418:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
21/05/202418:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/05/202408:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/05/202418:03PR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/05/202408:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/04/202408:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/04/202408:00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/04/202408:00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EPRX

Seu Histórico Recente

BIT
NSCIT5528426
Goldman Sachs
AQSE
GBS.GB
WisdomTree Commodity Sec...
BIT
F10851
Vontobel Financial Produ...
BIT
P1N9Z4
BNP Paribas Issuance
BIT
S28731
Societe Generale Effekten
BIT
FOFD
Franklin Future of Food ...
BIT
3BAS
WisdomTree Eur Stoxx Ban...
BIT
XNJP
Xtrackers Japan Net Zero...
BIT
FAMEUS
Fineco MSCIEUR HY SRI Co...
BIT
S29778
Societe Generale Effekten
BIT
P1JOA3
BNP Paribas Issuance BV
BIT
F11472
Vontobel Financial Produ...
BIT
XCS2
Australia SSA Bonds UCIT...
BIT
P1BW45
BNP Paribas Issuance
BIT
UB4GUW
Unicredit Bank
BIT
P228M7
NLBNPIT228M7 20991231 18...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios